GlassScriptPhysician profile
Selena Clearman
NPI 1518944560
$7,244.05
in general payments reported to CMS, 2019-2025
38 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,571 · 2022: $1,181 · 2023: $1,209 · 2024: $1,090 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,492.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,378.95 | 2021-2025 | |
| Novo Nordisk INC | $922.66 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $797.98 | 2021-2025 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $411.04 | 2021-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $390.90 | 2021-2022 | |
| Lilly USA, LLC | $372.89 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.07 | 2021-2024 | Jardiance |
| Amgen INC. | $348.84 | 2021-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $310.67 | 2021-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $264.01 | 2021 | |
| Merck Sharp & Dohme LLC | $172.74 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $143.54 | 2021 | |
| Shield Therapeutics INC | $142.46 | 2023-2024 | Accrufer |
| Pfizer INC. | $112.87 | 2021-2025 | |
| Exact Sciences Corporation | $112.84 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selena Clearman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.